TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Seagate Stock Jumps as AI-Fueled Earnings Beat and Strong FY2027 Outlook Impress Investors 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Philips Shares Slide 10% Despite Earnings Beat as Weak Orders Raise Growth Concerns 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
South Korea's Ministry of Food and Drug Safety revoked Medytox's permit for producing botulinum toxin products due to its use of unapproved ingredients and fabricating test results.
The three clostridium botulinum toxin products labeled Meditoxin sold in bottles of 50, 100, and 150 units will be permanently removed from the market beginning June 25.
The ministry also ordered Medytox to recall its Meditoxin products while urging local hospitals to participate in its removal.
The ministry had previously ordered a temporary suspension of the manufacture and sales of the three products.
An investigation found the pharmaceutical company repeatedly committing the infractions between 2012 and 2015.
The ministry, however, admitted that Meditoxin does not pose significant safety risks.
Meditoxin is effective in treating facial wrinkles, muscle spasms, and overactive muscle diseases.
Medytox received its first license for botulinum toxin production in 2006 and has since become South Korea's No. 2 producer of botulinum toxin products. It only trails Hugel Inc., which manufactures Botulax.
Meditoxin, which accounts for about 40 percent of Medytox's annual sales, takes up around 35 percent of the local market.
Medytox is in a lawsuit against local drugmaker Daewoong Pharmaceutical Co. over the patents of a botulinum toxin strain, claiming that the latter's Nabota uses the same formula as Meditoxin.
The International Trade Commission will make a preliminary ruling later this month.
